advertisement
Abstract #12442 Published in IGR 7-2
Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg
Henderer JD; Wilson RP; Moster MR; Myers J; Schmidt C; Fontanarosa J; Steinmann WCJournal of Glaucoma 2005; 14: 267-270
PURPOSE: To determine the intraocular pressure (IOP)-lowering effect of a fixed timolol/dorzolamide combination (Cosopt) for patients with IOP over 30 mmHg. STUDY DESIGN: Prospective interventional case series. METHODS: Eighteen patients being seen on the Wills Eye Hospital Glaucoma Service with at least one eye with an IOP > 30 mmHg were recruited. None had used any glaucoma medications for at least 1 month. IOP was confirmed by diurnal testing. Cosopt was administered at 9 am and 9 pm. Trough IOP measurements were made at 9 am and peak IOP measurements at 11 am at baseline, 1 month, and 2 months. Pretreatment and posttreatment IOPs were compared using a paired-samples independent t test. RESULTS: Mean pretreatment IOP was 37.5 ± 1.0 mmHg. Baseline posttreatment IOP was 18.4 ± 0.5 mmHg (P < 0.01). At 2 months, the mean trough IOP was 21.1 ± 0.9 mmHg and the peak, 17.6 ± 0.6 mmHg (each, P < 0.01, as compared with pretreatment baseline IOP). One patient did not respond to Cosopt; two had a clinically insufficient response and did not complete the study. Data from these patients were included in the analysis. CONCLUSIONS: Over 80% of the eyes responded to Cosopt, with an average trough IOP reduction of 40% at 2 months.
Dr. J.D. Henderer, William and Anna Goldberg Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University School of Medicine, Philadelphia, Pennsylvania 19107, USA. henderer@willsglaucoma.org
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
